Nine multiplaintiff lawsuits accusing major pharmaceutical companies of manufacturing and selling Zantac with high levels of a cancer-causing compound will be heading back to a Connecticut state court after a federal judge concluded that the defendants failed to show there was a “mass action” to trigger federal jurisdiction.

One of those cases was filed by Connecticut resident Beth Bacher, the representative for Paul Bacher, deceased, and 98 other plaintiffs from across the country who also claim they suffered personal injuries or death as the result of using the allegedly dangerous ranitidine-containing products designed and formulated over a 30-year period by the defendants, Boehringer Ingelheim, GlaxoSmithKline, Pfizer and Sanofi-Aventis.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]